Radiation Exposure Treatment
Medical Stocks To Buy
Featured on Money Info Show
The September 22, 2014 Money Info Investment news and small cap stocks to buy show featured a live interview with:
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
(NASDAQ Stock Symbol: CBLI)
Corporate Site: cbiolabs.com
Investors Conference Call Transcript — Click Here
Financials News – Click Here
Part 1 of the show
Options Trading Strategies | Options Trading Newsletter
Part 2 of the Show:
Radiation Exposure Treatment Medical Stocks To Buy
Cleveland BioLabs (CBLI) Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
Buffalo, NY – September 3, 2014 – Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company’s existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
See more at:
http://www.princetonresearch.com/medical-stock-news-cbli/
Radiation Exposure Treatment Drugs
Stock News
Just imagine the catastrophe if radioactive material falls into the wrong hands. The Russians have invested heavily in this. CBLI is involved in the development of Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, the lead oncology product candidate.
The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children’s Cancer Institute Australia.
To learn more about Cleveland BioLabs, Inc., please visit the Company’s website at http://www.cbiolabs.com.
Cleveland BioLabs (CBLI) Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
45%+ Upward Movement — See Report
Small Cap Medical Stock News:
Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612
— See News Here and http://irdirect.net/pr/release/id/886944
Cleveland BioLabs CEO Presents at FDA Update Conference
Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
— See News
Investment News Show
Money Info Show Airs
10 AM to 11 AM EDT
Every Tuesday
LISTEN LIVE
Use this Link To Watch The Show:
www.princetonresearch.com/money-info-live.htm
Be On The Air With Us
Call In Your Questions
888-792-1590
Money Info
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
Money Info is hosted by Mike King and Charles Moskowitz.